Skip to content

Foetal programming of allergic diseases

Foetal Programming of Allergic Diseases: an observational multicentre pregnancy cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN97827633
Enrollment
1300
Registered
2009-04-20
Start date
2009-10-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic diseases, e.g., atopic dermatitis, asthma and allergic rhinoconjuncitvitis Injury, Occupational Diseases, Poisoning Adverse effects, not elsewhere classified

Interventions

After written informed consent, the medical, obstetrical and gynaecological history will be thoroughly documented, and sociodemographic data (including smoking habits of pregnant mother and her partne

Sponsors

Individual sponsor (Germany)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women recruited at a gestational age of 8 - 12 weeks 2. Aged between 18 and 35 years old 3. Single child pregnancy 4. Full-term deliveries

Exclusion criteria

Exclusion criteria: 1. Fertility treatments and infections (human immunodeficiency virus [HIV], hepatitis B and C) 2. A history of recurrent spontaneous abortion, pre-eclampsia, or gestational diabetes in previous pregnancies 3. Sufferers of the following chronic diseases: 3.1. Inflammatory bowel diseases 3.2. Diabetes type 1 3.3. Rheumatoid and autoimmune diseases 3.4. Previous chemotherapies and radiation therapies

Design outcomes

Primary

MeasureTime frame
Evaluation of environmental cues as further potential risk factors during pregnancy (e.g. living conditions, smoking habits, perceived stress, social support and nutrition) for the child's risk to develop an atopic disease.

Secondary

MeasureTime frame
Investigation of potential mechanism, by which environmental cues may exert a foetal programming effect towards allergic diseases during pregnancy. Here we will concentrate on endocrine, immune and neurobiological mechanisms.

Countries

Canada, Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026